Bellicum Pharmaceuticals Inc (BLCM)

NASDAQ
1.480
+0.010(+0.68%)
  • Volume:
    38,071
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1.470 - 1.550

BLCM Overview

Prev. Close
1.47
Day's Range
1.47-1.55
Revenue
6.2M
Open
1.48
52 wk Range
1.38-8.15
EPS
1.16
Volume
38,071
Market Cap
12.35M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
121,769
P/E Ratio
1.27
Beta
1.34
1-Year Change
-66.51%
Shares Outstanding
8,397,803
Next Earnings Date
Mar 14, 2022
What is your sentiment on Bellicum Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Bellicum Pharmaceuticals Inc Company Profile

Employees
7

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. The Company has developed CAR-T product candidates in cellular immunotherapy through which a patient’s or donor’s T cells are genetically modified to carry chimeric antigen receptors (CARs). It uses a Chemical Induction of Dimerization (CID) technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. The Company's product candidates include BPX-601 and BPX-603. The BPX-601, is an autologous GoCAR-T product candidate containing iMC activation switch, designed to treat solid tumors expressing prostate stem cell antigen (PSCA). The BPX-603, is a controllable dual-switch autologous GoCAR-T product candidate, which incorporates both the iMC activation switch and the CaspaCIDe safety switch.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Sell
Technical IndicatorsStrong SellSellNeutralStrong SellStrong Sell
SummaryStrong SellStrong SellSellStrong SellStrong Sell
  • With today volume can this reach 20$ ?
    0
    • its on !⚡⚡
      0
      • the worst stock ever
        1
        • Achteruitgang van het aandeel,  in de naverkoop nochtans zien de . Kandelaarpatronen er zeer positief uit, of is het om eerst de prijs van het aandeel naar beneden te drukken alvorens men weder koopt?
          0
          • This the worst low volume bio stock to own because it trades regardless of news, usually opposite of good news, lost 70% value since ASH meeting despite no negative news, hardly gained 20% while ZIOP nearly tripled without news.
            0
            • What are people thinking about the return of this stock?
              1
              • $BLCM: Buy this stock before the big news!
                1
                • I bought this stock on the recommendation of a paid investment adviser. Since I bought the stock it is down about 15%. I was told that the stock was set to explode after a meeting it had with top pharmaceutical companies a few weeks ago to discuss some phase 2 test results. Supposedly the stock was set to "explode" in price after this meeting. Since then I have head nothing and he stock price has slowly gone down. The excuse is that the stock is in an overbought position. If the results of the phase 2 tests wee so good why haven't I heard about hem in the news media? That is what is needed to drive this stock. Otherwise, let me know what the status is so that I can invest my money somewhere else.
                  0
                  • It is going to explode. Hold your shares
                    0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.